Last reviewed · How we verify
Infanrix/Hib™ vaccine
Infanrix/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) bacteria.
Infanrix/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b (Hib) bacteria. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.
At a glance
| Generic name | Infanrix/Hib™ vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and Hib polysaccharide conjugate. These components trigger adaptive immune responses, generating protective antibodies and cellular immunity against these four pathogens. Upon exposure to the actual pathogens, the primed immune system rapidly produces antibodies to neutralize toxins and prevent infection.
Approved indications
- Prevention of diphtheria in infants and children
- Prevention of tetanus in infants and children
- Prevention of pertussis (whooping cough) in infants and children
- Prevention of Haemophilus influenzae type b (Hib) disease in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (PHASE3)
- Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (PHASE3)
- Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants. (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infanrix/Hib™ vaccine CI brief — competitive landscape report
- Infanrix/Hib™ vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI